EGFR+ Lung Cancer

A Chemoimmunotherapeutic Approach to Nondriver NSCLC

<em>Targeted Oncology</em>, a print and digital resource that offers content and expert opinions on precision medicine in oncology, launched its second &ldquo;Expert Perspective: Virtual Tumor Board&rdquo; on Wednesday, September 12. The Virtual Tumor Board is a video-editorial board discussion that features key opinion leaders from a specific oncological field. This episode will focus on non&ndash;small cell lung cancer.

A&nbsp;supplemental biologics license application for pembrolizumab (Keytruda) has been granted a priority review designation by the FDA for the frontline treatment of patients&nbsp;with locally advanced or metastatic nonsquamous or squamous non&ndash;small cell lung cancer with a PD-L1 expression level of &ge;1% and no <em>EGFR</em> or <em>ALK</em> genomic tumor aberrations.

Frontline pembrolizumab (Keytruda) has been approved by the European Commission for&nbsp;use in combination with standard chemotherapy as a treatment for patients with metastatic nonsquamous non&ndash;small cell lung cancer without <em>EGFR</em>&nbsp;or <em>ALK</em> mutations. The approval is&nbsp;based on results from the phase III KEYNOTE-189 trial.

The review period for a supplemental biologics license application seeking the approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel or the first-line treatment of patients with metastatic nonsquamous non&ndash;small cell lung cancer has been extended by the FDA.

Benjamin P. Levy, MD, clinical director of Medical Oncology at John Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses genotyping in lung cancer, particularly focusing on&nbsp;<em>ROS1&nbsp;</em>and&nbsp;<em>TRK&nbsp;</em>mutations.

Leading lung cancer researcher and clinician, Vassiliki A. Papadimitrakopoulou, MD, is the recipient of the 2018 Addario Lectureship Award presented by The Bonnie J. Addario Lung Cancer Foundation for her groundbreaking clinical research in immunotherapy.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;August 2018, including several new approvals, a priority review, breakthrough therapy designations, and more in a variety of cancer types.

Benjamin P. Levy, MD, discusses his clinical considerations for the management of non

In an interview with <em>Targeted Oncology</em>&nbsp;prior to the FDA approval of nivolumab in SCLC, Paul A. Bunn Jr, MD, discusses the potential agents for the treatment of SCLC, the challenges in treating this patient population, and the ongoing search for biomarkers to guide treatment decisions.